top of page
Pipeline
Programmable Cell Therapies for the Toughest Cancers
​
Our programs focus on cancers where TME-driven suppression limits cell therapy efficacy—using allogeneic, multiplex-edited immune cells designed to evade those barriers and deliver durable responses.
KiraLOGIC guides edit selection based on the dominant suppressive signals in each disease.
​
*All programs use an allogeneic chassis and are optimized for TME resistance.
​More than a pipeline: a blueprint for defeating immune suppression
bottom of page